Adolescent depression: what the evidence says actually helps

For adolescent depression, the treatment with the best trial evidence is the combination of an antidepressant, fluoxetine, with cognitive behavioural therapy; in the largest randomised trial it helped more adolescents than either approach alone [s1]. A later analysis pooling dozens of trials was more cautious, finding that only fluoxetine — by itself or with therapy — was clearly more effective than placebo, while most of the evidence base was of low quality [s2]. Effective treatments exist, in other words, but the certainty behind them is thinner than the subject's seriousness deserves.

The trial that anchors the field

The Treatment for Adolescents With Depression Study (TADS) randomly assigned 439 adolescents aged 12 to 17 with major depressive disorder to one of four conditions for 12 weeks: fluoxetine alone, cognitive behavioural therapy (CBT) alone, the two combined, or placebo [s1]. The combination performed best. Response rates were 71.0% for fluoxetine plus CBT (95% confidence interval 62% to 80%), 60.6% for fluoxetine alone (95% CI 51% to 70%), 43.2% for CBT alone (95% CI 34% to 52%), and 34.8% for placebo (95% CI 26% to 44%) [s1].

Two comparisons within those numbers matter. The combination was statistically superior to fluoxetine alone and to CBT alone, and fluoxetine alone was superior to CBT alone [s1]. That last point is often lost: in this trial, medication outperformed the talking therapy on its own over 12 weeks. The combination offered what the authors called the most favourable trade-off between benefit and risk [s1].

The safety signal, stated plainly

Depression trials in young people carry an unavoidable safety question, and TADS addressed it directly. Clinically significant suicidal thinking was present in 29% of the sample at the start, and it improved significantly in all four treatment groups, with the largest reduction in the fluoxetine-plus-CBT group [s1]. Over the trial, seven of the 439 participants (1.6%) attempted suicide, and there were no completed suicides [s1].

That pattern — overall improvement in suicidal thinking, alongside a small number of suicide-related events — is why regulators require close monitoring when antidepressants are started in this age group, and why guidelines pair medication with therapy and follow-up rather than prescribing in isolation. It is a reason for careful supervision, not for withholding effective treatment.

What the wider evidence base adds

A single trial, however large, is not the whole picture. A network meta-analysis brought together 71 trials covering 9,510 children and adolescents to compare antidepressants, psychotherapies and their combinations [s2]. Its conclusions were more sober than TADS alone would suggest. Only fluoxetine plus CBT and fluoxetine on its own were significantly more effective than pill placebo or psychological control conditions; among the psychotherapies, interpersonal therapy stood out as more effective than psychological controls [s2].

The crucial caveat is about certainty, not just ranking. The authors rated most of their results as "low" to "very low" confidence, and concluded that fluoxetine, alone or with CBT, "seems to be the best choice" while urging that the risks and benefits of any option be weighed case by case [s2]. That is a long way from a settled protocol, and it reflects how few high-quality trials this field has produced.

Where guidelines land

National guidance turns this evidence into a stepped approach. NICE recommends that children and young people with moderate to severe depression be offered a psychological therapy first, and that if an antidepressant is used it should be fluoxetine, combined with psychological therapy and with careful monitoring for any emergence of suicidal ideation [s3]. The logic is to reserve medication for those who need it, deliver it alongside therapy rather than instead of it, and watch closely at the start.

The trend data behind all of this are covered in our reporting on young people's mental health recovering unevenly, and the limits of the digital shortcut in mental-health apps aimed at teenagers. For treatments beyond the drug-and-therapy axis, see our coverage of exercise for depression and of which psychotherapy the evidence supports.

How to read this without overreaching

The honest summary is that adolescent depression is treatable, that the best-supported options are fluoxetine and CBT, and that combining them helped most in the largest trial — while the overall evidence base is smaller and weaker than the stakes warrant [s1] [s2]. What the evidence does not support is a one-size answer, or the idea that therapy alone is reliably sufficient for moderate-to-severe illness, or that medication should be started without monitoring.

The limits bound the claims. TADS ran for 12 weeks, so it speaks to acute treatment rather than to years of a young person's life [s1]; the network analysis rested largely on low-certainty trials [s2]; and none of this addresses prevention or milder, self-limiting low mood.

This article is informational and is not medical advice. It does not recommend any medication, dose, or treatment for an individual, and no one should start or stop treatment based on it. A young person who is struggling, or a family concerned about one, should seek help from a qualified clinician; if there is any immediate risk of harm, contact local emergency services or a crisis line.